The Journal of Clinical and Aesthetic Dermatology

Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology , discusses highlights from new research published in the August 2025 issue of JCAD.

Send us Fan Mail Dr. Del Rosso discusses advancements in photoprotection formulations, as well as recent FDA approvals that have expanded treatment options for rosacea and psoriasis.

Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology , discusses highlights from new research published in the June 2025 issue of JCAD.

Send us Fan Mail In this extended cut from JCAD’s recent Journal Review video series, Drs. Issa and Bunick dive into the possible mechanistic explanations behind arthralgia associated with dupilumab, which was detailed in a case series by Drs. Issa and Bunick and their colleagues in the May issue of The Journal of Clinical and Aesthetic Dermatology.

Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology , discusses highlights from new research published in the May 2025 issue of JCAD.

Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology , discusses highlights from new research published in the April 2025 issue of JCAD.

Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology , discusses highlights from new research published in the February 2025 issue of JCAD.

Send us Fan Mail Dr. James Del Rosso discusses a recent supplement that reviews insights about the challenges faced by both patients and clinicians in managing vitiligo.

Send us Fan Mail Dr. Del Rosso discusses potential adverse events that can occur when treating patients with trimethoprim-sulfamethoxazole.

Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology , discusses highlights from new research published in the January 2025 issue of JCAD.

Send us Fan Mail Dr. Del Rosso reviews some of the most impactful research developments and drug approvals seen by the dermatology world in 2024.

Send us Fan Mail Dr. Del Rosso discusses warning signs of serious adverse events related to trimethoprim-sulfamethoxazole prescribed to patients with acne.

Send us Fan Mail Dr. Song provides helpful clinical tips for treating patients with methotrexate. 

Send us Fan Mail Dr. Song provides an extensive overview of what’s new and emerging in atopic dermatitis treatment.

Send us Fan Mail Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the October 2024 issue of JCAD. 

Send us Fan Mail Dr. Del Rosso discusses three exciting new indications for drugs in dermatology and how these approvals will impact clinical practice. 

Send us Fan Mail Dr. Kircik discusses a recent FDA-approval of an IL-17 inhibitor that has demonstrated to be safe and effective in patients with psoriasis.

Send us Fan Mail Dr. Del Rosso discusses how to provide the correct treatment for the various presentations of psoriasis along with the impact psoriatic arthritis can have on these patients.

Send us Fan Mail Dr. Gelfand discusses how to treat patients with psoriasis in terms of cardiovascular risk. He encourages clinicians to educate their patients about these events and the potential side effects they present.

Send us Fan Mail Dr. Del Rosso discusses ways in which he’s modified his consultation style when speaking to patients with psoriasis who are about to commence treatment with a biologic.

Send us Fan Mail George Martin, MD, discusses the specific role TNF inhibitors play for the treatment of psoriasis along with an important safety implication to be aware of for treating patients during pregnancy.

Send us Fan Mail Dr. Del Rosso discusses biologic options for treating patients with psoriasis and psoriatic arthritis as well as pregnant patients.

Send us Fan Mail Dr. Stein Gold discusses insights from clinical trials on new and upcoming systemic agents for psoriasis, including deucravacitinib and bimekizumab. 

Send us Fan Mail George Martin, MD, discusses TNF inhibitors for the treatment of psoriasis and how these classic biologic agents currently fit into the ever-expanding arsenal of drugs for psoriasis.

Send us Fan Mail Raj Chovatiya, MD, PhD, Director of the Center for Eczema and Itch at the Department of Dermatology at Northwestern University Feinberg School of Medicine, reviews the mechanisms of action of currently available treatments for atopic dermatitis, including JAK inhibitors and biologic medications, and details how these medications work differently to reduce inflammation associated w...